GAT-1, encoded by SLC6A1, is one of the major gamma-aminobutyric acid (GABA) transporters in the brain and is responsible for reuptake of GABA from the synapse. In this study, targeted resequencing of 644 individuals with epileptic encephalopathies led to the identification of six SLC6A1 mutations in seven individuals, all of whom have epilepsy with myoclonic-atonic seizures (MAE). We describe two truncations and four missense alterations, all of which most likely lead to loss of function of GAT-1 and thus reduced GABA re-uptake from the synapse. These individuals share many of the electrophysiological properties of Gat1-deficient mice, including spontaneous spike-wave discharges. Overall, pathogenic mutations occurred in 6/160 individuals with MAE, accounting for~4% of unsolved MAE cases.
SLC6A1 (MIM 137165) encodes GAT-1, a voltage-dependent gamma-aminobutyric acid (GABA) transporter that is responsible for the re-uptake of GABA from the synapse. GABA is the principal inhibitory neurotransmitter that counterbalances neuronal excitation in the brain and disruption of this inhibitory balance can result in seizures. To date, mutations in SLC6A1 have not been shown to cause epilepsy in humans, although mutations in other genes that cause altered GABA signaling have been reported.
Overlapping 3p25.3 microdeletions have been reported in individuals with a wide spectrum of neurodevelopmental disorders. 1 Here, we describe a de novo 3p25.3 deletion in an individual with myoclonic-atonic epilepsy (MAE; also called myoclonic-astatic epilepsy or Doose syndrome; Table 1 ). This 315.6-kb deletion refines the critical interval to just two genes, SLC6A1 and SLC6A11 ( Figure S1 ). In addition, two single de novo SLC6A1 mutations in a cohort of individuals with intellectual disability and autism were reported by two independent, large exome sequencing studies. 2, 3 These molecular genetics studies, as well as the function of GAT-1 at the synapse, suggest that SLC6A1 is an excellent candidate gene for epileptogenesis.
To investigate the role of SLC6A1 in the etiology of the severe infantile and childhood epilepsies, we performed targeted resequencing in 569 individuals with a range of epileptic encephalopathies. Epileptic encephalopathies are a group of infantile-and childhood-onset epilepsies characterized by multiple seizure types and developmental delay or regression; they are associated with abundant epileptiform activity, which contributes to cognitive impairment. 4 All individuals or their parents or legal guardians gave informed consent to participate in the study and the institutional review boards of the University of Washington, and the University of Melbourne approved this study. We captured all 14 coding SLC6A1 exons and at least five base pairs of flanking intronic sequences by using molecular inversion probes (MIPs); next-generation sequencing, data analysis, and variant calling were performed as described previously. 5 In brief, we used MIPs and 100 ng of each proband's DNA to capture all target DNA and performed PCR with universal primers that contained a unique 8-bp barcode on the reverse primer. Amplified PCR products from all individuals were pooled and sequenced on an Illumina Hiseq according to a 101-bp paired-end protocol. We mapped raw reads to the genome (UCSC Genome Browser hg19) by using the BurrowsWheeler Aligner (BWA) and performed variant calling by using the Genome Analysis Toolkit (GATK). Variants that did not adhere to the following criteria were excluded from further analysis: allele balance > 0.75, quality (QUAL) < 30, quality by depth (QD) < 5, coverage < 503, and presence in homopolymer runs R4 bp. A threshold of 503 coverage was used for this methodology given that variants below this cut-off have a high false-positive rate; this is in contrast to other technologies, such as exome sequencing, which have a threshold of~203. Variants were annotated with SeattleSeq (see Web Resources), and the exome aggregation consortium (ExAC) dataset (see Web Resources) was used for assessments of variant frequency in the control population. Overall, we sequenced 90% of SLC6A1 to a depth of at least 503 and at an average coverage of 6523 across all samples ( Figure S2 ). We performed segregation analysis in parental DNA samples for all nonsynonymous, frameshift, and splice-site variants that were not present in the ExAC set of~61,000 exomes (see Web Resources). We performed segregation analysis on the proband and parental DNA by using Sanger sequencing with primers designed to flank
We identified four likely pathogenic SLC6A1 mutations in a cohort of 569 individuals with epileptic encephalopathies (Table 1, Table S1 , and Figure 1 ). All mutations adhered to the aforementioned criteria and occurred at a highly conserved nucleotide; none were present in ExAC, and each of the positions at which these mutations occurred was covered at a sequence depth of 203 or greater in the controls. In addition, amino acid changes were predicted to be damaging by one or more of the prediction tools (Polyphen2, Grantham, and SIFT; see Web Resources) 6 that we used (Table 1) . Moreover, we considered these variants to be likely pathogenic on the basis that they occurred de novo in the affected individual in three cases, and in one individual the variant was inherited from an unaffected mother who was a somatic mosaic for this mutation. By using a single molecular MIP (smMIP) that targeted this mutation as described previously 7 in the unaffected mother, we detected four alleles with the mutant C allele and 43 alleles with the reference allele. This suggests that approximately 18% of the mother's white blood cells carry the mutant allele. Strikingly, all individuals with SLC6A1 mutations showed phenotypic homogeneity 4 (Table 1) in that MAE is characterized by the onset of myoclonic, myoclonicatonic, and atonic seizures between 7 months and 6 years of age and the presence of generalized spike-wave or polyspike-wave discharges. Development prior to seizures is usually normal. 8 In our cohort, 85/569 individuals had a diagnosis of MAE for which no molecular cause had been previously identified. 5 This statistically significant enrichment of SLC6A1 mutations in MAE-affected probands (4/85) as compared to those with other epileptic encephalopathy phenotypes (0/484; p value 0.0005, Fisher's two-tailed test) prompted us to use the same methodology to screen this gene in an additional cohort of 75 individuals with MAE. In this validation cohort, we identified two additional SLC6A1 mutations (Table 1 and Figure 1 ). The c.578G>A (p.Trp193*) mutation arose de novo, whereas the c.863C>T (p.Ala288Val) mutation was inherited from a mother who also had MAE.
We performed further segregation analysis in the maternal grandparents and showed that the c.863C>T (p.Ala288Val) mutation arose de novo in the mother, who passed this mutation on to her affected daughter. Overall, in a cohort of 160 probands with MAE, we identified six SLC6A1 point mutations, accounting for~4% of previously unsolved MAE cases. SLC6A1 is widely expressed throughout developing and mature human, mouse, and rat brains, and its expression follows that of the GABAergic pathways.
9,10 GAT-1 is primarily located in the axon and nerve terminals of GABAergic interneurons, whereas GAT-3 is more abundant in astrocytes. [11] [12] [13] At the pre-synaptic terminal, GAT-1 3 In three-dimensional space, transmembrane domains 1-5 and 6-12 are folded such that the GABA binding pocket is between transmembrane domains 1 and 6. Thus, the four pathogenic missense substitutions all cluster around the GABA binding pocket and are likely to disrupt GABA transport from the extracellular space into the pre-synaptic terminal.
is responsible for the re-uptake of GABA from the synaptic cleft. This voltage-dependent transport requires the exchange of two sodium ions and one chloride ion for each GABA molecule.
14 In Gat1-deficient mice, GABA uptake is impaired, resulting in both increased ambient GABA levels and spontaneous spike-wave discharges. 16 We anticipate that the p.Arg44Gln substitution described here will have a similar negative effect on GABA uptake. Similarly, a p.Ala288Cys substitution reduced GABA transport activity to 5%-7% of the activity seen in wild-typelike GAT-1. 17 The p.Ala288Val substitution described here had the most damaging scores possible according to PolyPhen2 and SIFT and most likely results in loss of GAT-1 function. Although no mutagenesis data exist for the p.Gly297Arg alteration, Gly297, along with Ala61, Leu300, and Trp400, forms the GABA binding site. 18 Replacement of this small amino acid with a large positively charged residue is likely to occlude the GABA binding pocket. Finally, the p.Ala334Pro substitution occurs in transmembrane domain 7, and the presence of a large aromatic residue is likely to alter the conformation of this domain and disrupt function. In summary, although we have not performed mutagenesis studies for these specific substitutions, the evidence suggests that all six alterations could lead to a loss of function and reduced GABA uptake from the synapse, in a manner similar to that seen in Gat1-knockout mice. Given that GABA is the major inhibitory neurotransmitter in the brain, it seems paradoxical that increased GABA levels would cause seizures with hypersynchronous epileptiform neuronal activity. However, an elevation in ambient and synaptic GABA, due to decreased clearance, has the capacity to enhance both phasic and tonic inhibition. Increases in either of these two modes of inhibition have been associated with the appearance of spike-wave discharges. 19, 20 Moreover, Gat1-knockout mice, as well as mice administered a GAT-1 inhibitor, show spontaneous spike-wave discharges typical of absence seizures, 19 a seizure type seen in all individuals with SLC6A1 mutations. Finally, tiagabine, an antiepileptic drug that is effective in treating focal seizures and that blocks GAT-1 can cause both absence status epilepticus and myoclonic seizures in human subjects. 21, 22 These studies suggest that GABA function may extend beyond inhibition. Overall, we identified six likely pathogenic SLC6A1 mutations in seven individuals, including an affected mother and daughter, and an additional eighth individual with a deletion disrupting SLC6A1; all eight individuals have MAE (Table 1 ). The median age of seizure onset was 30.5 months (mean ¼ 26.1 months; range ¼ 12-38 months). All of these individuals had absence seizures, notably including eyelid myoclonia in four cases. All individuals also had drop attacks, which were myoclonic atonic in four individuals and atonic in the other four. Recording myoclonic-atonic seizures in a child with MAE can be challenging because formal video-EEG monitoring has shown that myoclonic, atonic, and myoclonic-atonic seizures can all occur in a single individual and can be hard to differentiate. 8 All individuals had generalized spike-waves >2.5 Hz on their EEGs, and four had a photoparoxysmal response. Seizures settled in three of the individuals, all children between the ages of 3 and 8 years; the remaining five individuals, aged 7 to 44 years, had ongoing seizures. Although the overall electroclinical pattern was consistent with MAE, atypical features were noted. Specifically, preceding developmental delay, which can occur in a minority of individuals with MAE, occurred in all eight individuals here. Developmental slowing or regression occurred in four individuals. All individuals had intellectual disabilities that ranged from mild to severe. Six individuals had autistic features. Tremors were marked in two individuals, one of whom also had ataxia. Another individual had prominent manual stereotypies. Also, generalized tonic-clonic seizures are frequently observed in MAE, [23] [24] [25] but only three of our individuals had this seizure type; of these three, two were the mother and daughter, who had catamenial generalized tonic-clonic seizures. Seven of the eight affected individuals, including the affected mother, were female, but this might simply reflect the relatively small cohort rather than true biological significance.
Interestingly, in a large exome sequencing study that focused on gene discovery under a de novo mutation model, the c.863C>T [p.Ala288Val] substitution was identified in an individual with autism spectrum disorder (13832.p1). 2 The clinical features of individual 13832.p1, as noted in the Simons Foundation Autism Research Initiative (SFARI; Table 1 ), indicate that this individual had absence seizures, regression, and autism, perhaps reflecting an overlapping phenotype with MAE. Interestingly, the median seizure onset for the three individuals with the p.Ala288Val substitution was 14 months, which is much earlier than that of the other six individuals described here, for whom the median onset was 33.5 months. Further studies are needed to determine whether this difference correlates with an underlying biological mechanism. We identified pathogenic SLC6A1 mutations in 6/160 probands with MAE, suggesting that mutations in this gene account for~4% of individuals with this severe epilepsy syndrome and are more likely in individuals with pre-existing developmental delay. We also describe a de novo deletion in one individual, whose phenotype was strikingly similar to that observed in individuals with SLC6A1 point mutations, despite the inclusion of the adjacent gene, SLC6A11 (MIM 607592), in the deletion. A genetic etiology for MAE has been proposed since its initial description by Doose and is supported by family studies. 26, 27 Family studies show that MAE can occur in a family with the familial epilepsy syndrome genetic epilepsy with febrile seizures plus (GEFSþ), although sporadic cases of MAE are often seen. 28 Several large families with GEFSþ, one of which includes an individual with MAE, have been described as having SCN1A (MIM 182389), SCN1B (MIM 600235), or GARBG2 (MIM 137164) mutations. [29] [30] [31] [32] [33] [34] Glucose transporter 1 deficiency has also been implicated in MAE, and SLC2A1 (MIM 138140) mutations have been found in a small subset (4/84) of MAE-affected individuals with both inherited and de novo mutations. 35 More recently, the role of de novo mutations in MAE has expanded given that mutations in GABRG2 (MIM 137164) have been identified in a single individual and mutations in CHD2 (MIM 602119) have been identified in two individuals. 5 Each of these genes contributes slightly to the etiology of MAE, but they are also associated with a wide spectrum of epilepsy phenotypes ranging from benign to severe. Mutations in SLC6A1 seem to occur specifically in individuals presenting with MAE. Although this observation requires further validation, it is supported by the lack of mutations in the remaining 484 individuals who had other epileptic encephalopathies and were sequenced in this study, as well as in 264 probands with infantile spasms or Lennox-Gastaut syndrome. 36 Collectively, these findings suggest that SLC6A1 mutations might cause a specific epilepsy syndrome: MAE that occurs in the context of abnormal early development. These early abnormalities might be due to the specific function of GAT-1 and GABA transport in the developing human brain. 
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